Gastric Bypass In A Pill: New Angles On Diabetes Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Emerging targets are looking at diabetes/obesity crossover, as well as immunometabolic approaches that overlap with dyslipidemia.